U.S. markets closed
  • S&P 500

    4,266.49
    +24.65 (+0.58%)
     
  • Dow 30

    34,196.82
    +322.58 (+0.95%)
     
  • Nasdaq

    14,369.71
    +97.98 (+0.69%)
     
  • Russell 2000

    2,333.62
    +30.15 (+1.31%)
     
  • Crude Oil

    73.27
    -0.03 (-0.04%)
     
  • Gold

    1,776.80
    +0.10 (+0.01%)
     
  • Silver

    26.03
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1935
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.4870
    0.0000 (0.00%)
     
  • GBP/USD

    1.3923
    -0.0041 (-0.29%)
     
  • USD/JPY

    110.8550
    -0.1070 (-0.10%)
     
  • BTC-USD

    34,735.60
    +1,240.79 (+3.70%)
     
  • CMC Crypto 200

    837.58
    +50.96 (+6.48%)
     
  • FTSE 100

    7,109.97
    +35.91 (+0.51%)
     
  • Nikkei 225

    28,875.23
    +0.34 (+0.00%)
     

Emergent BioSolutions's Single-Dose Chikungunya Vaccine Candidate Effective Even After Two Years of Vaccination

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Emergent BioSolutions Inc (NYSE: EBS) has announced two-year persistence data from its Phase 2 study evaluating its investigational chikungunya virus, virus-like particle (CHIKV VLP) vaccine candidate.

  • The CHIKV VLP vaccine is the only single-dose VLP-based vaccine currently in clinical development for active immunization against chikungunya disease, the company said.

  • Two years post-vaccination, serum neutralizing antibodies (SNA) responses were 19 times higher than pre-vaccination titers following a single adjuvanted 40 µg dose.

  • All subjects in the single-dose regimen remained seropositive at their one-year and two-year visits.

  • The vaccine candidate was well-tolerated, and no significant vaccine-related safety concerns were identified.

  • The majority of solicited adverse events were mild or moderate, and the most frequent were local injection site pain.

  • The company will publish the results of this study in the near term.

  • The CHIKV VLP vaccine candidate received the FDA Fast Track designation in May 2018 and EMA PRIME designation in September 2019.

  • Chikungunya virus is spread to people by infected mosquitoes.

  • Price Action: EBS shares are up 2.44% at $57.99 in the premarket session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.